IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?

IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?

Thu, September 10, 2026 at 4:56 PM GMT+3 2 min read

• IQV +1.74%

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $42.3 billion by market cap, the company offers analytics, technology solutions, and clinical research services to the life sciences industry which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.

Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.

More News from Barchart

Despite its notable strength, IQV slipped 5.5% from its 52-week high of $271.80, achieved on Sep. 4. Over the past three months, IQV stock gained 38%, outperforming the State Street Health Care Select Sector SPDR ETF's (XLV) 9.4% gains during the same time frame.

Shares of IQV rose 14% on a YTD basis and climbed 35.5% over the past 52 weeks, outperforming XLV's YTD gains of 8% and 21.7% returns over the last year.

To confirm the bullish trend, IQV has been trading above its 200-day moving average since early July. The stock has been trading above its 50-day moving average since early May, experiencing some fluctuations.

IQVIA outperformed on broad-based strength across clinical and commercial, driven by improved execution and healthier demand. CEO Ari Bousbib cited 19% growth in R&D net new bookings with a 1.22x book-to-bill and 5% growth in Commercial on new launches, while 294 AI agents across 90 use cases lifted win rates and efficiency, driving 90 bps of margin expansion. With momentum from the acquisition of select drug discovery assets from Charles River Laboratories International, Inc. (CRL) and continued investments in proprietary data, management raised guidance as CFO Michael Fedock noted productivity gains and strong bookings supporting momentum into next year.

In the competitive arena of diagnostics & research, Agilent Technologies, Inc. (A) has lagged behind IQV, with a 6.4% gain on a YTD basis and a 14.7% uptick over the past 52 weeks.

Wall Street analysts are bullish on IQV's prospects. The stock has a consensus "Strong Buy" rating from the 20 analysts covering it, and the mean price target of $277.16 suggests a potential upside of 7.9% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com